A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-small-cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2014
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 12 Oct 2009 Pharmacokinetic outcomes presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
- 01 Sep 2009 Pharmacokinetic outcomes have been reported at the 13th World Conference on Lung Cancer.
- 03 Aug 2009 Pharmacokinetic results presented at 13th WCLC.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History